Vir Biotechnology (VIR) Set to Announce Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR) is scheduled to announce its earnings results after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.99) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.28. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The company had revenue of $16.80 million for the quarter, compared to the consensus estimate of $11.18 million. During the same quarter in the prior year, the business posted ($0.76) EPS. The firm’s quarterly revenue was down 66.0% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Price Performance

Vir Biotechnology stock opened at $8.37 on Tuesday. Vir Biotechnology has a 12 month low of $7.61 and a 12 month high of $27.48. The business’s fifty day simple moving average is $9.90 and its two-hundred day simple moving average is $9.59.

Wall Street Analyst Weigh In

VIR has been the topic of a number of analyst reports. JPMorgan Chase & Co. upped their price target on shares of Vir Biotechnology from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Friday, February 23rd. HC Wainwright reiterated a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, March 15th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.38.

Insider Activity

In other news, EVP Ann M. Hanly sold 12,296 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $10.05, for a total transaction of $123,574.80. Following the transaction, the executive vice president now directly owns 134,780 shares of the company’s stock, valued at approximately $1,354,539. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, EVP Ann M. Hanly sold 12,296 shares of the company’s stock in a transaction dated Thursday, February 22nd. The shares were sold at an average price of $10.05, for a total transaction of $123,574.80. Following the completion of the sale, the executive vice president now owns 134,780 shares of the company’s stock, valued at approximately $1,354,539. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sung Lee sold 6,008 shares of the business’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $9.89, for a total transaction of $59,419.12. Following the sale, the chief financial officer now owns 100,492 shares of the company’s stock, valued at $993,865.88. The disclosure for this sale can be found here. Insiders have sold a total of 152,831 shares of company stock valued at $1,525,844 in the last 90 days. 15.60% of the stock is currently owned by insiders.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.